In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Xilio Therapeutics Inc (NASDAQ: XLO) closed at $0.70 down -34.57% from its previous closing price of $1.07. In other words, the price has decreased by -$34.57 from its previous closing price. On the day, 5.43 million shares were traded.
Ratios:
For a deeper understanding of Xilio Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.41 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 1.72. For the most recent quarter (mrq), Quick Ratio is recorded 1.96 and its Current Ratio is at 1.96. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Chardan Capital Markets on December 21, 2022, initiated with a Buy rating and assigned the stock a target price of $7.
On January 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $36.
On November 16, 2021, Raymond James started tracking the stock assigning a Outperform rating and target price of $31.Raymond James initiated its Outperform rating on November 16, 2021, with a $31 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 02 ’25 when Frankenfield Christopher James sold 6,954 shares for $0.98 per share. The transaction valued at 6,841 led to the insider holds 12,421 shares of the business.
Brennan Kevin M. sold 1,803 shares of XLO for $1,774 on Jan 02 ’25. The SVP, FINANCE AND ACCOUNTING now owns 3,197 shares after completing the transaction at $0.98 per share. On Dec 18 ’24, another insider, GILEAD SCIENCES, INC., who serves as the 10% Owner of the company, bought 1,759,978 shares for $1.04 each. As a result, the insider paid 1,830,377 and bolstered with 9,105,451 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.91 while its Price-to-Book (P/B) ratio in mrq is 3.39.
Stock Price History:
Over the past 52 weeks, XLO has reached a high of $1.70, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is -10.53%, while the 200-Day Moving Average is calculated to be -21.18%.
Shares Statistics:
A total of 51.78M shares are outstanding, with a floating share count of 16.42M. Insiders hold about 68.30% of the company’s shares, while institutions hold 8.39% stake in the company.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
A total of 1 analysts believe the company’s revenue will be $7.4M this quarter.It ranges from a high estimate of $7.4M to a low estimate of $7.4M. As of the current estimate, Xilio Therapeutics Inc’s year-ago sales were $2.36MFor the next quarter, 1 analysts are estimating revenue of $7.4M. There is a high estimate of $7.4M for the next quarter, whereas the lowest estimate is $7.4M.
A total of 1 analysts have provided revenue estimates for XLO’s current fiscal year. The highest revenue estimate was $25.1M, while the lowest revenue estimate was $25.1M, resulting in an average revenue estimate of $25.1M. In the same quarter a year ago, actual revenue was $6.34MBased on 1 analysts’ estimates, the company’s revenue will be $25.6M in the next fiscal year. The high estimate is $25.6M and the low estimate is $25.6M.
